Gwendolyn Binder - 20 Nov 2023 Form 4 Insider Report for Cabaletta Bio, Inc. (CABA)

Role
President, Science & Technology
Signature
By: /s/ Michael Gerard, as Attorney-in-Fact
Issuer symbol
CABA
Transactions as of
20 Nov 2023
Net transactions value
-$184,904
Form type
4
Filing time
21 Nov 2023, 16:30:32 UTC
Previous filing
19 Oct 2023
Next filing
19 Dec 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CABA Common Stock Options Exercise $11,110 +11,000 +55% $1.01* 31,000 20 Nov 2023 Direct F1
transaction CABA Common Stock Sale $61,608 -3,542 -11% $17.39 27,458 20 Nov 2023 Direct F1, F2
transaction CABA Common Stock Sale $134,405 -7,458 -27% $18.02 20,000 20 Nov 2023 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CABA Stock Option (Right to Buy) Options Exercise $0 -11,000 -8.2% $0.000000 122,756 20 Nov 2023 Common Stock 11,000 $1.01 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These transactions were effected pursuant to a Rule 10b5-1 trading plan dated January 20, 2023 adopted by the Reporting Person.
F2 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.90 - $17.89. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.90 - $18.24. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 This option vests over four years, with 25% vested on October 11, 2019, and the remaining shares vesting in 12 equal quarterly installments thereafter.

Remarks:

President, Science & Technology